Altimmune’s Pemvidutide shows positive topline results from IMPACT Phase IIb trial
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Subscribe To Our Newsletter & Stay Updated